| P2093 | author name string | Xiangdong Liu | |
| | Peggy A Scherle | |
| | Robert C Newton | |
| P2860 | cites work | Molecular cloning and expression of human hepatocyte growth factor | Q24305558 |
| | Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis | Q24683896 |
| | Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily | Q27654013 |
| | SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo | Q27658318 |
| | MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 |
| | Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 |
| | Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Q27851633 |
| | Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis | Q28139783 |
| | Met, metastasis, motility and more | Q28235183 |
| | A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family | Q28285975 |
| | Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis | Q28295920 |
| | Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor | Q28307227 |
| | Scatter factor/hepatocyte growth factor is essential for liver development | Q28504542 |
| | Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud | Q28506228 |
| | Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses | Q28513246 |
| | Epidermal growth factor receptor mutations in lung cancer | Q29615474 |
| | Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells | Q33922202 |
| | c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention | Q34422211 |
| | Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. | Q34454578 |
| | An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms | Q34625881 |
| | Drug development of MET inhibitors: targeting oncogene addiction and expedience | Q34782774 |
| | c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases | Q35199181 |
| | Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation | Q35277738 |
| | Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells | Q36090650 |
| | Signaling networks assembled by oncogenic EGFR and c-Met | Q36392991 |
| | RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors | Q36540061 |
| | The mutationally activated Met receptor mediates motility and metastasis | Q36735738 |
| | Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia | Q36988579 |
| | Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer | Q37111358 |
| | Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells | Q37141943 |
| | Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer | Q37293236 |
| | Novel therapeutic inhibitors of the c-Met signaling pathway in cancer | Q37422804 |
| | Molecularly targeted therapies for thyroid cancers. | Q37527371 |
| | Clinical implications of MET gene copy number in lung cancer | Q37690299 |
| | Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele | Q37705080 |
| | MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor | Q38432619 |
| | Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma | Q38466547 |
| | Missense mutation of the MET gene detected in human glioma | Q38525862 |
| | ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. | Q39702478 |
| | E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models | Q39787136 |
| | Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. | Q39813764 |
| | Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma | Q40004623 |
| | AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts | Q40050768 |
| | Identification of genes that modulate sensitivity of U373MG glioblastoma cells to cis-platinum | Q40240700 |
| | MET overexpression turns human primary osteoblasts into osteosarcomas. | Q40285015 |
| | Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma | Q40333091 |
| | Somatic mutations lead to an oncogenic deletion of met in lung cancer | Q40333112 |
| | Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation | Q40408804 |
| | HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion | Q40490783 |
| | Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels | Q40546756 |
| | Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. | Q40761395 |
| | A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth | Q40765252 |
| | c-met proto-oncogene expression in benign and malignant human prostate tissues | Q40981774 |
| | Amplified met gene linked to double minutes in human glioblastoma | Q41584617 |
| | Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. | Q42454085 |
| | Scatter factor is a fibroblast-derived modulator of epithelial cell mobility | Q42807925 |
| | Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo | Q42809563 |
| | Novel mutations of the MET proto-oncogene in papillary renal carcinomas. | Q42815807 |
| | Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia | Q43212290 |
| | c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. | Q44810921 |
| | Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells | Q44986030 |
| | Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas | Q45345804 |
| | Molecular cloning of a new transforming gene from a chemically transformed human cell line. | Q45345810 |
| | Prognostic significance of c-Met expression in glioblastomas | Q46170165 |
| | Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin | Q46176116 |
| | MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma | Q46379055 |
| | c-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice. | Q51828709 |
| | c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. | Q52122642 |
| | Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma. | Q53221535 |
| | Frequent amplification of the c-met gene in scirrhous type stomach cancer. | Q53486015 |
| | Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. | Q53875696 |
| | Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. | Q54158447 |
| | Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. | Q54584505 |
| | Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma. | Q54699355 |
| | Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. | Q55043279 |
| | Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. | Q55284672 |
| | Amplification of the MET gene in glioma. | Q55481480 |
| | Effect of c-Met Expression on Survival in Head and Neck Squamous Cell Carcinoma | Q57765077 |
| | Comparison of hepatocyte growth factor levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts | Q75421957 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1225-1241 | |
| P577 | publication date | 2011-07-11 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Development of c-MET pathway inhibitors | |
| P478 | volume | 20 | |